Breast Cancer Outcomes at a Tertiary Hospital in Yenagoa, Nigeria
Article Sidebar
Main Article Content
Abstract
Objective: This retrospective study aimed to identify factors influencing treatment outcomes among female patients diagnosed with breast cancer in a tertiary hospital.
Methods: Data from 84 female patients diagnosed with breast cancer were analyzed. Demographic and clinical characteristics were examined, along with treatment modalities. Treatment outcomes were categorized as good or poor, and logistic regression was used to identify predictors of treatment outcome.
Results: The mean age of patients was 47.11 years, with the 40–49 age group being the most represented (33.3%). A majority of patients had no family history of breast cancer (75.0%) and reported no history of alcohol (81.0%) or tobacco use (92.9%). The commonest presenting symptom was a painless breast lump (78.6%), with 61.9% of patients presenting > 6 months after symptom onset. Surgery and chemotherapy were performed in 86.9% and 64.3% of cases, respectively. Statistical significance for all analyses was set at p < 0.05. Bivariate analysis showed significant associations between treatment outcomes and both duration of symptoms (p = 0.049) and chemotherapy (p < 0.001). Logistic regression identified duration of symptoms ≤ 6 months (OR = 3.01; 95% CI: 1.01–9.00; p = 0.049) and receipt of chemotherapy (OR = 12.77; 95% CI: 3.95–41.25; p < 0.001) as the independent predictors of good treatment outcomes.
Conclusion: Early presentation and receipt of chemotherapy were associated with good treatment outcomes among female breast cancer patients in this study. Strategies to promote early detection and improve access to chemotherapy are essential for enhancing treatment outcomes.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
How to Cite
References
1.Joko-Fru WY, Miranda-Filho A, Soerjomataram I, Egue M, Akele-Akpo MT et al Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and human development index: A population-based registry study. Int J Cancer. 2020 146(5):1208-1218. doi: 10.1002/ijc.32406.
2.Atoyebi SB, Awodutire PO, Igbalajobi MM, Anifowose OO. Survival times of breast cancer patients in Nigeria. Asian J Immunol. 2023;6(1):209-23.
3.Jedy-Agba E, McCormack V, Olaomi O, Badejo W, Yilkudi et al Determinants of stage at diagnosis of breast cancer in Nigerian women: sociodemographic, breast cancer awareness, health care access and clinical factors. Cancer Causes Control. 2017 28(7):685-697. doi: 10.1007/s10552-017-0894-y.
4.Olaogun JG, Agodirin OS, Idowu DB. Patient delay in initiating treatment after breast cancer diagnosis: A cause for concern. J Health Sci Res. 2024; 9:55-9. doi: 10.25259/JHSR_48_2023.
5.Olayide AS, Halimat AJ, Samuel OA, Ganiyu RA, Soliu OA. Level of awareness and knowledge of breast cancer in Nigeria. A systematic review. Ethiop J Health Sci. 2017 Mar 15;27(2):163-74. doi: 10.4314/ejhs.v27i2.9.
6.Adeniji AA, Dawodu OO, Habeebu MY, Oyekan AO, Bashir MA et al. Distribution of Breast Cancer Subtypes Among Nigerian Women and Correlation to the Risk Factors and Clinicopathological Characteristics. World J Oncol. 2020 Aug;11(4):165-172. doi: 10.14740/wjon1303.
7.Ginsburg O, Yip CH, Brooks A, Cabanes A, Caleffi M et al. Breast cancer early detection: A phased approach to implementation. Cancer. 2020 May 15;126 Suppl 10(Suppl 10):2379-2393. doi: 10.1002/cncr.32887.
8.Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Aug 1;30(8):1194-1220. doi: 10.1093/annonc/mdz173.
9.Saldaña-Téllez M, Meneses-Navarro S, Cano-Garduño L, Unger-Saldaña K. Barriers and facilitators for breast cancer early diagnosis in an indigenous community in Mexico: voices of Otomí women. BMC Womens Health. 2024 Jan 13;24(1):33. doi: 10.1186/s12905-023-02875-2.
10.George TO, Allo TA, Amoo EO, Olonade O. Knowledge and Attitudes about Breast Cancer among Women: A Wake-Up Call in Nigeria. Open Access Maced J Med Sci. 2019 May 25;7(10):1700-1705. doi: 10.3889/oamjms.2019.221.
11.Uwimana A, Dessalegn S, Vianney Dusengimana JM, Stauber C, Fata A, Hagenimana M et al. Integrating breast cancer early detection into a resource-constrained primary health care system: health care workers' experiences in Rwanda. JCO Global Oncol. 2022 Dec;8: e2200181.
12.12.Riis M. Modern surgical treatment of breast cancer. Annals of medicine and surgery. 2020 Aug 1; 56:95-107.
13.Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat. 2014 Feb;144(1):1-10. doi: 10.1007/s10549-014-2852-7.
14.Folorunso SA, Abiodun OO, Abdus-Salam AA, Wuraola FO. Evaluation of side effects and compliance to chemotherapy in breast cancer patients at a Nigerian tertiary hospital. Ecancermedicalscience. 2023 Apr 21; 17:1537. doi: 10.3332/ecancer.2023.1537.
15.Omisore AD, Olasehinde O, and Wuraola FO, et al (2023) Improving access to breast cancer screening and treatment in Nigeria:the triple mobile assessment and patient navigation model (NCT05321823): a study protocol PLoS One 18(6) e0284341 https://doi.org/10.1371/journal.pone.0284341
16.Azubuike SO, Muirhead C, Hayes L, McNally R. Rising global burden of breast cancer: the case of sub-Saharan Africa (with emphasis on Nigeria) and implications for regional development: a review. World J Surg Oncol. 2018 Dec;16(1):189. doi: 10.1186/s12957-018-1489-x
17.Kantelhardt EJ, Zerche P, Mathewos A, Trocchi P, Addissie A et al. Breast cancer survival in Ethiopia: a cohort study of 1,070 women. Int J Cancer. 2014 Aug 1;135(3):702-9. doi: 10.1002/ijc.28691.
18.Vanderpuye V, Grover S, Hammad N, Prabhakar P, Simonds H, Olopade F, et al. An update on the management of breast cancer in Africa. Infect Agent Cancer. 2017 14; 12:13. doi: 10.1186/s13027-017-0124-y.
19.Ofuya M. Overcoming barriers to early breast cancer presentation in Nigeria. Lancet Oncol. 2024 Jul;25(7):840. doi: 10.1016/S1470-2045(24)00319-X.